Medical Condition News

RSS

Transcendental Meditation significantly reduces PTSD, anxiety, and burnout in nurses during COVID-19

Frontline nurses who learned the Transcendental Meditation technique during the COVID-19 pandemic showed rapid and significant improvements in flourishing, PTSD, anxiety, and burnout over 3 months compared to controls, according to a study published today in the Journal of Nursing Administration.

11 Dec 2023

Non-invasive cancer monitoring takes a leap forward with new microfluidic technology

Monitoring cancer cells effectively can help physicians with treatment and management, thus reducing cancer-related mortality.

11 Dec 2023

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.

11 Dec 2023

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

11 Dec 2023

New drug combo shows promise in targeting RAS-mutant multiple myeloma

The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

New organoid model could revolutionize neuroendocrine tumor research

The Organoid Group (Hubrecht Institute) and the Rare Cancers Genomics Team (IARC/WHO) found a way to grow samples of different types of neuroendocrine tumors (NETs) in the lab.

11 Dec 2023

Study provides a better understanding of how the brain responds to injuries

A new study published in Proceedings of the National Academy of Sciences Nexus provides a better understanding of how the brain responds to injuries.

11 Dec 2023

Advanced MRI offers insights into the underlying mechanisms of neurological problems after COVID-19

Researchers at Linköping University have examined the brains of 16 patients previously hospitalized for COVID-19 with persisting symptoms.

11 Dec 2023

Empowering communities: Know Diabetes by Heart initiative awards grants to combat cardiovascular disease

The American Diabetes Association and the American Heart Association have awarded grants to 10 community organizations to help people living with Type 2 diabetes lower their risk for cardiovascular diseases like heart attack, heart failure and stroke.

11 Dec 2023

New report provides latest update on cardiovascular disease burden and trends

A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely to heart disease each year, according to the new Global Burden of Disease (GBD) special report published today in the Journal of the American College of Cardiology.

11 Dec 2023

Medical Condition News

Transcendental Meditation significantly reduces PTSD, anxiety, and burnout in nurses during COVID-19

Non-invasive cancer monitoring takes a leap forward with new microfluidic technology

New combinations and targeted therapies for acute myeloid leukemia on the horizon

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

New drug combo shows promise in targeting RAS-mutant multiple myeloma

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

New organoid model could revolutionize neuroendocrine tumor research

Study provides a better understanding of how the brain responds to injuries

Advanced MRI offers insights into the underlying mechanisms of neurological problems after COVID-19

Empowering communities: Know Diabetes by Heart initiative awards grants to combat cardiovascular disease

New report provides latest update on cardiovascular disease burden and trends

Is there an association between meat and fish consumption and non-alcoholic fatty liver disease?

Groundbreaking online community connects Progeria patients worldwide

Researchers develop novel exosome-based drug delivery system to treat Alzheimer's disease

New map offers valuable insights into the underlying mechanisms of neurodevelopmental disorders and cancer

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News